- Eurobiomed, cluster de référence pour l’innovation et l’industrialisation des entreprises en santé dans le Sud de la France, a accompagné en 2025 22 projets de R&D pour 124 M€ de financements publics mobilisés pour ses entreprises membres dans les régions Sud et Occitanie.
- In 2025, HealthTech companies in the South and Occitanie regions obtained €309 million in private funding, including €160 million from Eurobiomed member companies, confirming the region's dynamism and the cluster's structuring role in accessing financing.
- Au total, l’action du cluster a contribué à mobiliser 284 M€ de financements publics et privés pour ses entreprises membres, confirmant le dynamisme du territoire et le rôle structurant d’Eurobiomed dans l’accès aux financements.
- Eurobiomed has a record of over 300 missions supporting and connecting healthcare companies, laboratories, university hospitals, institutional players, and investors.
- Three strategic health priorities identified for 2026: immunotherapy and regenerative medicine, digital health, and dermatology & skin sciences.
Marseille, February 10, 2026 – Eurobiomed, a leading cluster for innovation and industrialization of HealthTech companies in southern France, has published its 2025 report and confirmed its role as a strategic accelerator for the development of sectors, financing, and industrialization of HealthTech innovations in the South and Occitanie regions, covering the cities of Toulouse, Montpellier, Nice, Sophia Antipolis, and Marseille.
More than 22 R&D projects supported by Eurobiomed in 2025 in a context of highly selective investors
In 2025, Eurobiomed confirmed its role as a structuring cluster in an environment that has become particularly demanding. HealthTech companies now have to contend with a new financing regime and increased complexity in terms of clinical, regulatory, and industrial trajectories. Even though France has excellent health research, transforming innovation into industrial solutions that are truly accessible to patients remains a major challenge. In this context, Eurobiomed has established itself as a key player in structuring the healthcare sector in the south of France and supports companies in scaling up their innovations into fundable, industrializable, and marketable projects.
In 2025, Eurobiomed's strategic support resulted in more than 300 support missions and qualified networking opportunities between companies, laboratories, university hospitals, institutional players, and investors.
Au total, les entreprises membres d’Eurobiomed dans les régions Sud et Occitanie ont obtenu 284 M€ de financements publics et privés en 2025.
Ce montant se compose de 124 M€ de financements publics obtenus pour 22 projets de R&D accompagnés par le cluster, dont 100 M€ via France 2030, et de 160 M€ de financements privés pour les entreprises membres accompagnées par Eurobiomed au cours de l’année.
At the regional level, all healthcare companies in the South and Occitanie regions obtained €309 million in private funding in 2025. Eurobiomed member companies alone accounted for more than half of this private funding, raising €160 million in the region.
Of the €309 million in private funding raised by all companies in the South and Occitanie regions in 2025, €192.1 million (62%) relates to biotechnology, €86 million (28%) to medtech, €20 million (6%) to diagnostics, and €11 million (4%) to digital health.
This momentum has resulted in several iconic industrial and financial successes. MedinCell has taken a decisive step forward with the commercialization of its long-acting injectable treatment in the United States. ImCheck Therapeutics has been acquired by the French biopharmaceutical group Ipsen, confirming the attractiveness of innovations developed in the region. Finally, in 2025, Adcytherix raised €105 million in Series A funding, the largest fundraising round for a French biotech company in 2025.
A growing community with more than 100 new members joining Eurobiomed in 2025 and a strengthened panel of experts
With 432 members, including 106 new members in 2025, Eurobiomed has reached its highest ever membership level. This high re-engagement rate reflects the relevance of support based on a comprehensive approach, combining strategic support, targeted networking with clinical and industrial players, and assistance in accessing funding.
Focus on the Eurobiomed expert panel
Eurobiomed draws on a pool of nearly 60 high-level experts from industry, academia, and research, who are mobilized to support HealthTech companies at every stage of their development. In 2025, in addition to scientific experts dedicated to supporting R&D projects, Eurobiomed has established a pool of experts comprising successful entrepreneurs and industrialists, such as Pierre d'Epenoux, CEO of ImCheck Therapeutics, Fabienne Hermitte, co-founder of Ipsogen, and Christine Guillem, CEO of Angany.
Tailor-made support mechanisms created by Eurobiomed to secure financing and scaling-up for companies
In order to provide operational and strategic support to companies in a context of highly selective financing and industrial and scientific partnerships, Eurobiomed has structured a range of support services tailored to the different stages of maturity of companies through dedicated premium programs.
Focus on the Invest In Biomed program, dedicated to financing strategies
The Invest In Biomed program, dedicated to supporting HeathTech companies in their fundraising strategies, illustrates Eurobiomed's ability to effectively connect the ecosystem with investors. In 2025, it brought together 9 innovative companies and 37 specialized investors, resulting in more than 130 BtoB meetings.
Orchestrated with 15 Eurobiomed experts, the support program focused on strategic business diagnosis, understanding investor expectations, and structuring value propositions. The highlight of the program, held in Marseille, gave companies the opportunity to present their projects to specialized investors and receive immediate operational feedback. As a result, a company such as Eka Surgery, which is developing an artificial intelligence platform to assist surgeons, was able to engage in active discussions with financial partners, while Circle Safe, which had previously participated in an Invest In Biomed program, raised €8 million in 2025 for its innovative solution to secure atrial fibrillation ablation procedures.
Three strategic healthcare sectors with high potential identified for 2025–2026
Eurobiomed promotes a sector-based approach to supporting healthcare companies and identifies areas with strong growth potential, in line with the maturity of the HealthTech ecosystem and the projects present in its territories. Eurobiomed has therefore focused its actions on three priority sectors: immunotherapies and regenerative medicine, digital health, and dermatology and skin sciences.
Immunotherapies and regenerative medicine, driven in particular by the dynamism of the Marseille Immunology Biocluster, are at the heart of the innovative therapies market. These applications represent one of the most dynamic segments of the global pharmaceutical industry, with a market valued at several hundred billion dollars.
Digital health is establishing itself as a cross-cutting driver of innovation and transformation in healthcare systems. The global digital health market is estimated to be worth more than $400 billion by 2025, driven by the rise of artificial intelligence and connected medical devices.
Focus on dermatology and skin science: Skin Excellence by Eurobiomed, a unique international project
Eurobiomed has decided to prioritize the structuring of the dermatology and skin science sector, a segment at the crossroads of medical dermatology, cosmetics, and biotechnology. The globalskincare market is estimated to be worth around $178 billion in 2025, while the more specialized dermocosmetics segment, at the interface between cosmetics and health, is worth nearly $48 billion and is showing sustained growth.
With more than 80 players, including startups, academic laboratories, industrial companies, and hospitals, the skin sector in Occitanie and the South region already accounts for nearly 4,000 jobs and represents strong growth potential. Based on this mapping, Eurobiomed has begun work on the operational structuring of the sector, focusing on four areas:
- Mapping stakeholders to guide Skin Excellence's priority themes and target relevant connections between stakeholders.
- Visibility and networking, with the launch of the official Skin Excellence website and partnerships with major organizations such as La Roche-Posay, Beiersdorf, and
- Organization of major events. For example, the first Skin Summit brought together nearly 200 participants from more than 10 countries, positioning the skin industry in the south of France at an unprecedented level in terms of international influence. Building on this success, a second edition will be organized in 2027.
- The development of structuring projects to support innovation and industrialization. Eurobiomed has notably worked on the project engineering of the Skin Experimentation Third Place, a facility designed to facilitate the testing and validation phases of innovations in skin health, funded to the tune of €1 million by France 2030.
Outlook for 2026: value chains, industrialization, and the rise of premium programs
In 2026, Eurobiomed intends to continue and expand the action initiated in 2025 to accelerate the scaling up of HealthTech companies in the Région Sud Occitanie Région Sud . The cluster intends to continue structuring its strategic sectors with the aim of accelerating their internationalization.
Eurobiomed also plans to consolidate and expand its panel of experts in order to provide entrepreneurs with even more detailed support in defining and executing their development strategies, beyond mere financing issues. This initiative will be accompanied by the launch of a support program dedicated to CROs (private research services companies for the pharmaceutical industry). Finally, Eurobiomed plans to roll out a support program dedicated to bringing digital health tools to market.
Emilie Royère, Managing Director of Eurobiomed, concludes:
HealthTech companies no longer expect just support for innovation or access to financing. They need comprehensive strategic support that covers their entire journey, from project structuring to industrialization and market access.
In 2025, Eurobiomed strengthened this position by providing concrete support to companies at these key stages, whether in terms of structuring complex projects, financing, regulation, networking, or preparing for industrialization. The results achieved, both in terms of network dynamics and the scaling up of the companies supported, confirm the relevance of this approach.
In 2026, we will continue our commitment to structuring strategic sectors capable of producing French HealthTech champions on the international stage.
About Eurobiomed
Eurobiomed is the leading cluster for innovation and industrialization in the HealthTech sector in southern France. It brings together more than 430 stakeholders, companies, research institutions, clinical, industrial, and institutional players in Occitanie and the South regions—Provence-Alpes-Côte-d'Azur and Occitanie/Pyrénées-Méditerranée.
Eurobiomed supports HealthTech companies at every stage of their development, from research to commercialization, and facilitates qualified connections with key players in the healthcare ecosystem (university hospitals, technology platforms, manufacturers, financiers, investors). By structuring sectors and scaling up innovations, Eurobiomed helps to strengthen the sovereignty and competitiveness of French HealthTech.
Press Contacts
Agence NewCap
Nicolas Merigeau
+33 (0)1 44 71 94 98
Gaëlle Fromaigeat
+33 (0)6 58 16 33 76
